iSpecimen Inc
NASDAQ:ISPC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2601
2.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
iSpecimen Inc
Research & Development
iSpecimen Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
iSpecimen Inc
NASDAQ:ISPC
|
Research & Development
-$1.5m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Research & Development
-$750.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-29%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Research & Development
-$108.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Research & Development
-$93m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Research & Development
-$92m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Research & Development
-$48.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
iSpecimen Inc
Glance View
iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. The company is headquartered in Lexington, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2021-06-17. The firm designed iSpecimen Marketplace platform to transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. The Company’s marketplace platform ingests de-identified healthcare data provided by healthcare supply partners. The iSpecimen Marketplace supports the supply chain management and bioprocurement process for specimens and associated data. The Company’s platform helps with administrating and reporting function for researchers, suppliers, and internal personnel, including user and compliance management. The firm serves to biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions.
See Also
What is iSpecimen Inc's Research & Development?
Research & Development
-1.5m
USD
Based on the financial report for Dec 31, 2024, iSpecimen Inc's Research & Development amounts to -1.5m USD.
What is iSpecimen Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-56%
Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for iSpecimen Inc have been -71% over the past three years , -56% over the past five years .